Jan 12, 2021 · Tessera Therapeutics said Tuesday at the J. Most recently, David served as Chief Medical Officer of bluebird bio for nearly a decade, where he played a critical role in advancing a broad Jun 20, 2024 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to Finance and Operations Executive. See what employees say it's like to work at Tessera Therapeutics. 11. Apr 22, 2024 · Tessera Therapeutics, a biotechnology company pioneering a new approach to genome engineering through the development of its Gene Writing™ and delivery platforms, today announced six presentations of new preclinical data at the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place in Baltimore, Maryland, May 7 Geoffrey von Maltzahn. Gene Writing writes curative therapeutic messages into the genome. Moore co-founded Apr 23, 2024 · Tessera Therapeutics, Flagship’s major bet on what it calls gene writing, is letting go 13% to 14% of its workforce, a spokesperson confirmed to Endpoints News. Holmes has over 20 years of experience working on the development and clinical translation of different genome editing- and gene therapy-based strategies for the treatment of inherited and acquired diseases. A healthy brain is our greatest asset. Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicia ns the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. CRISPR is the best known gene editing technology, following upon Zinc-Finger nucleases, TALENs, and meganucleases. +1 more. Tessera Therapeutics primarily serves the healthcare and medical research sectors. From 2016-2021, she served as Chief Scientific Officer at Moderna where she led the early-stage research teams developing Moderna’s platform technologies in mRNA design and delivery. The Galien Foundation fosters, recognizes and rewards excellence in scientific innovation to improve the May 10, 2024 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to Apr 19, 2022 · Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health Gene Therapy. While these methods are offering potential cures for select diseases, they are not without significant limitations. The company's main service is Gene Writing, a new genome engineering technology that writes therapeutic messages into the genome to treat diseases at their source. Tessara utilises the RealBrain ® 3D micro-tissue platform to accelerate neural drug discovery and regenerative medicine projects both in house and with our partners. Hari Pujar. Michael joined Tessera in December 2021 as Chief Scientific Officer. John V. Tessera Therapeutics develops a toolkit of Gene Writers to make nearly any type of genomic alteration needed to treat or cure disease. Manufacture Gene Writer mRNA and template RNA. Michael Severino joined Flagship in 2022 and serves as CEO-Partner and Chief Executive Officer of Tessera Therapeutics. Steve Garbacz joined Tessera in 2021 as the Head of Finance and is responsible for financial reporting, planning, taxes, and treasury. Tessera was founded by Flagship Who is Tessera Therapeutics. It can specifically and efficiently direct diverse alterations to the genome, in any type of cell Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Biotechnology. This is the Tessera Therapeutics company profile. , April 22, 2024 (GLOBE NEWSWIRE) -- Tessera Therapeutics, a biotechnology company pioneering a new approach to genome engineering through the development of its Gene Writing™ and delivery platforms, today announced six presentations of new preclinical data at the upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting taking place in Baltimore, Maryland . 7 out of 5, based on over 18 reviews left anonymously by employees. Apr 19, 2022 · Tessera Therapeutics Corrals More Than $230 Million for New Genetic Medicines. Apr 22, 2024 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to Apr 19, 2022 · Tessera Therapeutics, a company developing a genetic approach to treat and prevent diseases with backing from Flagship Pioneering, raised more than $300 million in its latest round. Apr 22, 2024 · By Tessera Therapeutics. mRNA-encoded Gene Writer and tem Jul 7, 2020 · Not anymore, says Geoffrey von Maltzahn, the CEO of a new startup called Tessera Therapeutics. Jun 2, 2022 · Tessera Therapeutics stacks up more than $300M in series C funds to bolster new gene-editing platforms. tesseratherapeutics. Hari is Chief Operating Officer of Tessera, as well as Operating Partner at Flagship Pioneering. Glassdoor gives you an inside look at what it's like to work at Tessera Therapeutics, including salaries, reviews, office photos, and more. The biotech startup is developing genetic medicine that cures diseases by allowing scientists and clinicians to write therapeutics into the human genome. 04. He is an inventor, entrepreneur, CEO, and the co-founder of multiple groundbreaking companies that integrate biology and data science 4 days ago · April 23 - Tessera Therapeutics: About 13-14% of employees, or 50 people are being let go from Tessera as the biotech shifts from preclinical to clinical development. Geoffrey von Maltzahn joined Flagship Pioneering in 2009. He has a passion for building scalable financial May 10, 2024 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to Feb 8, 2024 · Co-op, LNP Formulations and Characteristics. com Oct 27, 2023 · SOMERVILLE, Mass. Feb 28, 2022 · Tessera Therapeutics was founded by Flagship Pioneering, a life sciences enterprise that conceives, resources, and develops first-in-category bioplatform companies to transform human health and Senior Analyst, Digital Identity and Applications Somerville, Massachusetts, United States Add Benefits. 6 out of 5, based on over 45 reviews left anonymously by employees. By Tessera Therapeutics. Tessera Therapeutics www. Prior to joining Tessera, he was Chief Financial Officer and Chief May 2, 2023 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. For more information about Tessera, please visit www. Tessera Therapeutics and Fulcrum Therapeutics share similar industries and employee estimates. P. Tessera Therapeutics is a biotech company that develops gene writing technology for genetic medicine. , October 27, 2023 -- Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as Gene Writing, today announced it was awarded the Prix Galien USA 2023 in the Best Startup category. The company is pioneering a new category of genome engineering technology called Gene Writing and establishing a new field of genetic medicine. D, and Noubar Afeyan Ph. David brings over 20 years of expertise in clinical drug development focused on rare diseases and gene therapy. Michael Severino has served as CEO of Tessera Therapeutics, a… · Experience: Tessera Therapeutics · Education: The Johns Hopkins University · Location: Cambridge · 500 Jan 9, 2023 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to Company Summary: Tessera Therapeutics is pioneering Gene Writing™— a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages Michael Severino. in funding over 3 rounds. Tessera Therapeutics is a life sciences company with a focus on genetic medicine and biotechnology. Jul 7, 2020 · About Tessera TherapeuticsTessera Therapeutics is an early-stage life sciences company pioneering Gene Writing™, a new biotechnology designed to offer scientists and doctors the ability to write April 19, 2022. He has a proven track record of translating genomic engineering Apr 18, 2023 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Health Care. Longevity Vision Fund and SALT Fund are the most recent investors. Stephen Garbacz. Omenn Collegiate Professor of Human Genetics and a Professor of Internal Medicine at the University of Michigan Medical School. D, Geoffrey von Maltzahn Ph. Michael Severino. Follow its LinkedIn page to see updates on its research, programs, events, and achievements. Genetics. May 10, 2024 · Tessera Therapeutics presents new data on its Gene Writing and delivery platforms for genome engineering at ASGCT 2024. Jun 15, 2021 · Tessera Therapeutics’ new technology could write therapeutic messages into genomes, treating genetic diseases at their source. The company shows progress on in vivo correction of mutations for AATD, SCD, PKU, WD, and CAR-T cells. We deliver our RNA Gene Writers as all RNA products using proprietary lipid nanoparticles or LNPs. Does Tessera Therapeutics pay their employees May 10, 2024 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to Jun 18, 2024 · Mike Holmes, PhD, Chief Scientific Officer at Tessera Therapeutics. Apr 17, 2024 · Tome’s first order of business was to snap up Replace Therapeutics to expand its toolkit to one equipped to make gene edits in DNA sequences big and small. Jun 2, 2022 · Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Anne Shelton, M. Tessera Since June 2022, Dr. Dec 8, 2021 · Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. $531. The result is Tessera Therapeutics. During the past 21+ years, Dr. 51% of employees would recommend working at Tessera to a friend and 34% have a positive outlook for the business. David joined Tessera in 2021 as Chief Medical and Development Officer. Dr. Does Tessera pay their employees well? Aug 9, 2017 · Experience: Tessera Therapeutics · Education: Simmons College · Location: Boston · 500+ connections on LinkedIn. Howard Liang joined Tessera in 2021 as President and Chief Financial Officer. Gene Writing holds the potential to become a new category in genetic medicine, Nov 3, 2021 · Tessera Therapeutics was founded by Flagship Pioneering, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and Tessera Therapeutics Biology Gene Writing Delivery Focus Areas Leadership Careers News Contact Contact info@tesseratx. Gene therapy is largely divided between ex vivo and in vivo approaches. This rating has decreased by 2% over the last 12 months. Process. com. May 19, 2023 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to At Tessera, we are advancing our Gene Writing™ technology and proprietary LNP delivery system to alter the human genome and effect precise, durable therapeutic change to cure even the most challenging genetic diseases. 2023 | News May 19, 2023 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Howard brings nearly three decades of combined experience in management, financing, strategy, and research in the biotechnology and pharmaceutical industries and investment research on Wall Street. Dr Holmes has over 20 years of experience working on the development and clinical translation of different genome editing- and gene therapy-based strategies for the treatment of inherited and acquired diseases. Experience in:<br><br>Financial Planning, Reporting &… · Experience: Tessera Therapeutics · Education: New York University - Leonard N. About Tessara. has 23 executives +1 617 868 1888; Add an executive. Moran is the Gilbert S. Organizational Chart of Tessera Therapeutics. D. We envision a future where we can treat each disease at its source by designing the optimal Gene Writing system for a given Apr 19, 2022 · Tessera Therapeutics, founded and created by life sciences VC staple Flagship Pioneering, is building a war chest with a fresh $300 million for its trio of gene writing platforms. All content is posted anonymously by employees working at Tessera Therapeutics. View Elisabeth Boucher’s profile on LinkedIn, a professional community of 1 Apr 22, 2024 · SOMERVILLE, Mass. Stern School of When was Tessera Therapeutics founded? Tessera Therapeutics was founded in 2018. Read more. Compare pay for popular roles and read about the team’s work-life balance. Contact. Geoffrey von Maltzahn is co-founder and board chair of Tessera Therapeutics, as well as a general partner at Flagship Pioneering. The well-funded Boston biotech Tessera Therapeutics was founded by Flagship Pioneering in 2018, a life sciences innovation enterprise that conceives, resources, and develops first-in-category companies to transform human health and sustainability. View Rahul Palchaudhuri’s profile on LinkedIn, a professional community Sep 22, 2023 · Tessera has an overall rating of 3. Unlock for free. Morgan Healthcare Conference that it has raised more than $230 million in its second round of funding. Company Summary: Tessera Therapeutics is pioneering Gene Writing™— a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages into the genome, thereby curing diseases at their source. Gene Writing uses RNA or DNA templates to write or rewrite the genome without double stranded breaks. His roles have spanned from discovery research to carrying many FDA-approved treatments to Jun 6, 2024 · The estimated total pay range for a Associate Director at Tessera Therapeutics is $187K–$263K per year, which includes base salary and additional pay. 8M. A little more than a year after raising $230 million in a series B financing round, Tessera Therapeutics tapped investors again, this time raising more than $300 million in a series C financing to support the buildout of its Gene Writing platforms and development of multiple therapeutic programs. D, Jacob Rubens Ph. This rating has decreased by 1% over the last 12 months. Mike brings more than two decades of biopharmaceutical leadership and significant contributions to the research, development, registration, and commercialization of more than a dozen approved therapies. , April 19, 2022 – Tessera Therapeutics, the biotechnology company pioneering a new approach in genetic medicine known as GENE WRITING technology, announced today that it has raised over $300 million in Series C financing. 2024 | Press Release Tessera Therapeutics to Present New Data Across Preclinical Programs for its Gene Writing™ and Delivery Platforms at the American Society of Gene and Cell Therapy 27th Annual Meeting By Tessera Therapeutics. Hari is a global Biopharmaceutical executive with 20+ years of value creation in the biologics and vaccine industry. Gene Writing holds the potential to become a new May 10, 2024 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to May 19, 2023 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Prior to that, Dr. Jan 12, 2021 · Tessera Therapeutics Inc. Get the inside scoop on jobs, salaries, top office locations, and CEO insights. Company Summary: Tessera Therapeutics is pioneering Gene Writing™— a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages Find out what works well at Tessera Therapeutics from the people who know best. The company, founded in 2018 by Boston-based biotech investing powerhouse Flagship Pioneering, where Tessera Therapeutics to Present New Data Showcasing the Broad Potential of its Gene Writing™ and Delivery Platforms at the American Society of Gene and Cell Therapy 26th Annual Meeting. Steve has more than 25 years of experience in financial management for a range of companies, including Biogen, Epizyme, Spero, and Anika. 48% of employees would recommend working at Tessera Therapeutics to a friend and 42% have a positive outlook for the business. , a biotechnology startup pioneering new types of genetic medicines, has raised more than $230 million in venture capital as it prepares to start its initial clinical trials. Most gene editing technologies, including CRISPR, evolved to destroy the DNA of invading viruses. Uncover why Tessera Therapeutics is the best company for you. At Tessera, his responsibilities span across research, manufacturing, program strategy and management and IP. In recent years, we’ve made extraordinary leaps in genetic medicine, with two pillar technologies emerging: gene therapy and gene editing. LNPs can safely and effectively deliver nucleic acids to cells without eliciting a robust immune response as is common with viral delivery vectors. 2023 | Press Release. While gene therapy is the most widely used genetic medicine to treat genetic disorders, there are still many limitations. Tessera Therapeutics's Social Media Sep 2, 2021 · The same goes for Geoffrey von Maltzahn, CEO of Tessera Therapeutics and a general partner at Flagship Pioneering. Researchers harness this biology by modifying Breakthrough 3D human brain models. Photo: Geoffrey von Maltzahn, co Biopharmaceutical executive with experience in vaccine, biologics, mRNA, small molecule… · Experience: Tessera Therapeutics · Education: University of Pennsylvania - The Wharton School Melissa Moore is a renowned scientist with over three decades of experience in RNA research and pharmaceutical development. D are the founders of Tessera Therapeutics. Michael joined Tessera in 2022 as Chief Executive Officer and a CEO-Partner at Flagship Pioneering. Their latest funding was raised on Apr 19, 2022 from a Series C round. 07. Tessera is using a protein borrowed from the retrotransposition machinery of Jan 12, 2021 · Tessera Therapeutics, the Boston-based spin-up from Flagship Pioneering, is the latest company to enter the mix with $230 million in new financing to build up its platform for better biological David Davidson. May 10, 2024 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to Jul 14, 2021 · About Tessera Therapeutics Tessera Therapeutics is an early-stage life sciences company pioneering Gene Writing, a new biotechnology designed to offer scientists and clinicians the ability to Jan 12, 2021 · Tessera Therapeutics is pioneering “gene writing,” a kind of genetic medicine it hopes will surmount the limitations of gene editing and gene therapy—and investors have bet more than $230 May 19, 2023 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to Apr 22, 2024 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to Nature has evolved an efficient way to write genes: mobile genetic elements. Apr 19, 2022 · Somerville, Mass. Apr 20, 2022 · Tessera Therapeutics has collected over $300 million in Series C funding from a subsidiary of the Abu Dhabi Investment Authority, SoftBank Vision Fund 2, Artis Ventures and others. , Ph. Apr 24, 2021 · ・Tessera Therapeuticsでは、MGEを利用したGene Writing™という独自技術プラットフォームを開発している。Gene Writing™には、人工的に作られたMGEを用いて、①RNAによる遺伝子導入と②DNAによる遺伝子導入の2つの技術がある。 Gene editing is a revolutionary technology but has practical limitations in many cases. The average Associate Director base salary at Tessera Therapeutics is $172K per year. CRISPR technology, a gene editing tool that can be used to splice and alter the DNA inside a cell, has for years been hailed as the future of genetic disease medicine. 2023 | News Apr 22, 2024 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to May 2, 2023 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to Company Summary: Tessera Therapeutics is pioneering Gene Writing™— a new biotechnology designed to offer scientists and clinicians the ability to write small and large therapeutic messages Nov 7, 2023 · For more in-depth perspectives on what makes for a great place to work, we also spoke with the chief human resources officers at Tessera Therapeutics, this year’s top finisher among small companies, and Moderna, which earned the top spot in the large company category for the third year in a row. "As a result of positive data Tessera Therapeutics has raised a total of. Pioneering Gene Writing™, a new biotechnology designed to offer the ability to make almost any change to the genome curing diseases at their source. Moran’s laboratory has been at the forefront of human transposable element research and has made discoveries about the mechanism of Long Interspersed Experience: Tessera Therapeutics · Education: Harvard University · Location: Cambridge · 500+ connections on LinkedIn. Cambridge, Massachusetts, United States 108 Contacts101-250 employees. Tessera is Jan 9, 2023 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to Feb 5, 2023 · Tessera Therapeutics was founded in 2018 by Flagship Pioneering, a life sciences innovation enterprise that conceives, creates, resources, and develops first-in-category bioplatform companies to transform human health and sustainability. Fulcrum Therapeutics is a biotechnology company that focuses on identifying and treating rare genetic diseases at their root cause. . 22. 18. Who is the founder of Tessera Therapeutics? Robert Citorik Ph. Standing Out as a Small Company May 7, 2024 · Tessera Therapeutics has an overall rating of 3. Ex vivo therapies, like CAR-T cell therapies, use retroviral vectors to deliver corrective DNA directly to cells outside of the body. Tessera Therapeutics is funded by 13 investors. wx zb rb ez bw gv op pr fq dl